Daré Bioscience Earnings Call Transcripts
Fiscal Year 2026
-
Two revenue-generating products are launching in 2026, supported by a scalable digital health platform and strong provider relationships. Late-stage clinical programs for contraception and HPV are set for key data readouts next year, with a robust pipeline fueled by non-dilutive funding.
-
A pivotal period is underway with new product launches, including Flora Sync LF5 and DARE to PLAY, and major clinical milestones expected next year for Ovaprene and DARE-HPV. The strategy leverages grant funding, digital engagement, and provider relationships for capital-efficient growth.
-
Transitioning to a commercial-stage company, the business launched its first product and is preparing a second for prescription dispensing, with a third targeted for 2027. Financials show improved net loss and increased revenue, supported by non-dilutive funding and a scalable commercial platform.
-
The event detailed a transition from development to commercialization, with two products—Flora Sync LF5 and DARE to PLAY—launching in 2024, supported by a robust pipeline and over $75 million in non-dilutive funding. Key clinical milestones for Ovaprene and DARE-HPV are expected in the next year, while the business model leverages digital platforms and provider networks for rapid adoption.
-
The meeting covered eight proposals, including director elections, auditor ratification, and amendments to the stock incentive plan. All proposals were approved, with no questions from stockholders.
-
Transitioning to a revenue-generating phase, first product revenue is expected in June 2026, with strong clinical and commercial momentum across a robust women's health pipeline. Cash runway is limited, but diversified capital sources and positive clinical milestones support growth.
-
A broad women's health pipeline is advancing, with imminent launches for topical sildenafil cream and vaginal probiotics, and a non-hormonal contraceptive in phase III. Strategic partnerships, grant funding, and innovative commercialization pathways are driving growth and near-term revenue.
Fiscal Year 2025
-
DARE to PLAY, a topical sildenafil cream, launched pre-fulfillment prescribing nationwide with revenue expected in Q2 2026. The pipeline includes multiple differentiated women's health products, supported by strong grant funding and disciplined capital management.
-
Q3 2025 saw strong execution of a dual-path strategy, with DARE to PLAY Sildenafil Cream on track for commercial launch and multiple pipeline products advancing. Cash position was bolstered by equity and grant funding, while R&D expenses declined due to non-dilutive support.
-
Accelerated dual-path strategy is driving near-term revenue opportunities, with DARE to PLAY Sildenafil cream on track for Q4 2025 launch and Ovaprene phase III progressing. Post-quarter capital raises and grants have strengthened liquidity, supporting continued pipeline advancement.
-
Plans to commercialize four women's health products via dual-path strategy, with first revenue expected in Q4 2025. Q1 saw reduced expenses and a $4.4M loss, with strong cash position and grant funding supporting ongoing development and partnerships.
-
The event detailed a robust pipeline targeting major unmet needs in women's health, with key products like sildenafil cream and Ovaprene advancing through late-stage development and innovative dual-path market strategies. Revenue from new launches and strategic partnerships is expected in 2024.
Fiscal Year 2024
-
Plans to launch proprietary sildenafil cream via 503B compounding in Q4 2025, accelerating access and revenue while pursuing FDA approval. 2024 saw reduced expenses, new non-dilutive funding, and pipeline progress, but Ovaprene Phase III faces enrollment delays due to federal funding issues.
-
Secured over $20 million in non-dilutive funding, reduced expenses, and advanced late-stage women's health candidates. Ovaprene and sildenafil cream programs progressing, with key milestones and expanded clinical sites expected in 2025.
-
Q2 saw reduced expenses and a $12.9M comprehensive income, driven by a royalty monetization deal. Ovaprene and Sildenafil Cream remain top priorities, with phase III progress and FDA feedback pending. XACIATO prescriptions are growing, and menopause programs are advancing.